Acadia Pharmaceuticals (ACAD) either didn’t receive — or is ignoring — the Big Pharma etiquette memo about easing back on egregious drug-price hikes.
During the fourth quarter, the San Diego-based company acknowledged Tuesday night, it took two price increases for Nuplazid, a pill used to quell hallucinations and delusions often experienced by people with advanced Parkinson’s disease.
In October, it raised the price of Nuplazid by 19 percent, and then, in December, the company pushed through another 9 percent price hike. (Acadia also increased Nuplazid’s price last April.) Today, a year’s worth of the drug costs approximately $32,400, according to GoodRx. That’s about 35 percent more than when the drug was launched in the middle of 2016.
About the Author Reprints
